Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced its lead COVID-19 vaccine candidate demonstrated strong protection against SARS-CoV-2 in pre-clinical studies. The investigational Ad26.COV2.S vaccine showed robust immune responses and near-complete lung protection in non-human primates. Following this success, a Phase 1/2a clinical trial involving over 1,000 healthy adults has commenced in the U.S. and Belgium, with plans for a pivotal Phase 3 trial starting in September. The company aims to produce over one billion doses by 2021, pending safety and efficacy.
Johnson & Johnson (NYSE: JNJ) announced a cash dividend of $1.01 per share for Q3 2020, payable on September 8, 2020. Shareholders of record as of the close of business on August 25, 2020 will receive this dividend, with an ex-dividend date of August 24, 2020. This announcement reflects the company's commitment to maintaining shareholder returns amidst its extensive healthcare initiatives aimed at improving access and affordability for communities worldwide.
Johnson & Johnson (NYSE: JNJ) reported Q2 2020 earnings, highlighting a 10.8% decline in reported sales to $18,336 million compared to $20,562 million in 2019. Net earnings also dropped by 35.3% to $3,626 million. The Pharmaceutical segment grew by 3.9%, driven by key products, despite a 33.9% decline in Medical Devices due to COVID-19 impacts. The company is committed to advancing a COVID-19 vaccine on a not-for-profit basis. Regulatory approvals for multiple treatments were also announced.
On July 6, 2020, Johnson & Johnson (NYSE: JNJ) partnered with the Stop TB Partnership, Global Fund, and USAID to enhance access to SIRTURO® (bedaquiline) for low- and middle-income countries. The company reduces the price to USD$340 per six-month treatment, supporting over 135 countries. Free goods will be provided based on order volume, potentially saving USD$16 million for national TB programs in the first year. This agreement aims to combat DR-TB amid the COVID-19 pandemic, aligning with WHO treatment guidelines.